WELLESLEY, Mass., Feb. 26 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. , today announced that Robert L. Bratzler, Ph.D., Coley's President and Chief Executive Officer, plans to provide a corporate presentation at Susquehanna Financial Group's SIGnificant Investment Options in Healthcare Conference on March 1, 2007 at 2:00 p.m. at the Omni Berkshire Place in New York, NY.
Interested parties may access an audio webcast of the presentation by visiting the Coley Pharmaceutical Group website at http://www.coleypharma.com. A replay of the webcast will be archived on the "Investor Events" page in the Investor Center section of the Coley website for two weeks until March 15, 2007
About Coley Pharmaceutical Group
Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, asthma and allergy and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, Novartis Vaccines, GlaxoSmithKline and the United States government. For further information on Coley Pharmaceutical Group please visit www.coleypharma.com.
Coley Pharmaceutical Group, Inc.CONTACT: Susan Hager, Senior Director, Investor Relations and CorporateCommunications, Coley Pharmaceutical Group, +1-781-431-9079, orshager@coleypharma.com, or Karen L. Bergman or Michelle Corral of BCCPartners (US), +1-650-575-1509 or +1-415-794-8662, orkbergman@bccpartners.com, or mcorral@bccpartners.com, both for ColeyPharmaceutical Group
Web site: http://www.coleypharma.com//
